Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: In vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737

Cancer Letters

Volumn 317, Issue 2, 2012, Pages 218-225

  Ishitsuka, Kenji ^a   Kunami, Naoko ^a   Katsuya, Hiroo ^a   Nogami, Rumiko ^a   Ishikawa, Chie ^b   Yotsumoto, Fusanori ^a   Tanji, Hiroe ^b   Mori, Naoki ^b   Takeshita, Morishige ^a   Miyamoto, Shingo ^a   Tamura, Kazuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

ABT 737; Apoptosis; ATLL; Bcl 2 family proteins; Novel treatment

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; DOXORUBICIN; ETOPOSIDE; PROTEIN BCL 2; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA; TUMOR VOLUME;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOHISTOCHEMISTRY; JURKAT CELLS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; MICE, SCID; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; T-LYMPHOCYTES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 84856616427     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.030     Document Type: Article

References (46)

1. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br. J. Haematol. 1991, 79:428-437.
2. Hermine O., Allard I., Levy V., Arnulf B., Gessain A., Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol. J. 2002, 3:276-282.
3. Tsukasaki K., Hermine O., Bazarbachi A., Ratner L., Ramos J.C., Harrington W., O'Mahony D., Janik J.E., Bittencourt A.L., Taylor G.P., Yamaguchi K., Utsunomiya A., Tobinai K., Watanabe T. Definition Prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 2009, 27:453-459.
4. Yamada Y., Tomonaga M., Fukuda H., Hanada S., Utsunomiya A., Tara M., Sano M., Ikeda S., Takatsuki K., Kozuru M., Araki K., Kawano F., Niimi M., Tobinai K., Hotta T., Shimoyama M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br. J. Haematol. 2001, 113:375-382.
5. Tsukasaki K., Utsunomiya A., Fukuda H., Shibata T., Fukushima T., Takatsuka Y., Ikeda S., Masuda M., Nagoshi H., Ueda R., Tamura K., Sano M., Momita S., Yamaguchi K., Kawano F., Hanada S., Tobinai K., Shimoyama M., Hotta T., Tomonaga M. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J. Clin. Oncol. 2007, 25:5458-5464.
6. Fukushima T., Miyazaki Y., Honda S., Kawano F., Moriuchi Y., Masuda M., Tanosaki R., Utsunomiya A., Uike N., Yoshida S., Okamura J., Tomonaga M. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 2005, 19:829-834.
7. Kato K., Kanda Y., Eto T., Muta T., Gondo H., Taniguchi S., Shibuya T., Utsunomiya A., Kawase T., Kato S., Morishima Y., Kodera Y., Harada M. Allogeneic bone marrow transplantation from unrelated human T-Cell leukemia virus-I-negative donors for adult T-cell Leukemia/Lymphoma: retrospective analysis of data from the Japan marrow donor program. Biol. Blood Marrow Transplant. 2007, 13:90-99.
8. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. Bcl-2 inhibitors small molecules with a big impact on cancer therapy. Cell Death Differ. 2008.
9. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 2007, 117:112-121.
10. Stolz C., Hess G., Hahnel P.S., Grabellus F., Hoffarth S., Schmid K.W., Schuler M. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 2008, 112:3312-3321.
11. Kline M.P., Rajkumar S.V., Timm M.M., Kimlinger T.K., Haug J.L., Lust J.A., Greipp P.R., Kumar S. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007, 21:1549-1560.
12. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.X., Sneed T., Verhaegen M., Soengas M., Ruvolo V.R., McQueen T., Schober W.D., Watt J.C., Jiffar T., Ling X., Marini F.C., Harris D., Dietrich M., Estrov Z., McCubrey J., May W.S., Reed J.C., Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
13. Kang M.H., Kang Y.H., Szymanska B., Wilczynska-Kalak U., Sheard M.A., Harned T.M., Lock R.B., Reynolds C.P. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110:2057-2066.
14. Olejniczak E.T., Van Sant C., Anderson M.G., Wang G., Tahir S.K., Sauter G., Lesniewski R., Semizarov D. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol. Cancer Res. 2007, 5:331-339.
15. High L.M., Szymanska B., Wilczynska-Kalak U., Barber N., O'Brien R., Khaw S.L., Vikstrom I.B., Roberts A.W., Lock R.B. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol. Pharmacol. 2010, 77:483-494.
16. Wilson W.H., O'Connor O.A., Czuczman M.S., LaCasce A.S., Gerecitano J.F., Leonard J.P., Tulpule A., Dunleavy K., Xiong H., Chiu Y.L., Cui Y., Busman T., Elmore S.W., Rosenberg S.H., Krivoshik A.P., Enschede S.H., Humerickhouse R.A. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010, 11:1149-1159.
17. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., Hann C.L., McKeegan E.M., Litvinovich E., Hemken P.M., Dive C., Enschede S.H., Nolan C., Chiu Y.L., Busman T., Xiong H., Krivoshik A.P., Humerickhouse R., Shapiro G.I., Rudin C.M. Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. J. Clin. Oncol. 2011.
18. Mori N., Fujii M., Ikeda S., Yamada Y., Tomonaga M., Ballard D.W., Yamamoto N. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999, 93:2360-2368.
19. Bernal-Mizrachi L., Lovly C.M., Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. USA 2006, 103:9220-9225.
20. Mahieux R., Pise-Masison C., Gessain A., Brady J.N., Olivier R., Perret E., Misteli T., Nicot C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001, 98:3762-3769.
21. Nicot C., Mahieux R., Takemoto S., Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000, 96:275-281.
22. Mori N., Fujii M., Cheng G., Ikeda S., Yamasaki Y., Yamada Y., Tomonaga M., Yamamoto N. Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways. Virus Genes 2001, 22:279-287.
23. Miyoshi I., Kubonishi I., Sumida M., Hiraki S., Tsubota T., Kimura I., Miyamoto K., Sato J. A novel T-cell line derived from adult T-cell leukemia. Gann 1980, 71:155-156.
24. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 1980, 77:7415-7419.
25. Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Ohtsuki Y., Shiraishi Y., Nagata K., Hinuma Y. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981, 294:770-771.
26. Nabeshima K., Shimao Y., Inoue T., Koono M. Immunohistochemical analysis of IQGAP1 expression in human colorectal carcinomas: its overexpression in carcinomas and association with invasion fronts. Cancer Lett. 2002, 176:101-109.
27. Ishitsuka K., Hideshima T., Hamasaki M., Raje N., Kumar S., Podar K., Le Gouill S., Shiraishi N., Yasui H., Roccaro A.M., Tai Y.Z., Chauhan D., Fram R., Tamura K., Jain J., Anderson K.C. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 2005, 24:5888-5896.
28. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
29. Temmink O.H., Hoogeland M.F., Fukushima M., Peters G.J. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother. Pharmacol. 2006, 57:171-179.
30. Kuwazuru Y., Hanada S., Furukawa T., Yoshimura A., Sumizawa T., Utsunomiya A., Ishibashi K., Saito T., Uozumi K., Maruyama M., et al. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990, 76:2065-2071.
31. Ohno N., Tani A., Uozumi K., Hanada S., Furukawa T., Akiba S., Sumizawa T., Utsunomiya A., Arima T., Akiyama S. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood 2001, 98:1160-1165.
32. Takemoto S., Mulloy J.C., Cereseto A., Migone T.S., Patel B.K., Matsuoka M., Yamaguchi K., Takatsuki K., Kamihira S., White J.D., Leonard W.J., Waldmann T., Franchini G. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc. Natl. Acad. Sci. USA 1997, 94:13897-13902.
33. Tomita M., Kikuchi A., Akiyama T., Tanaka Y., Mori N. Human T-cell leukemia virus type 1 tax dysregulates beta-catenin signaling. J. Virol. 2006, 80:10497-10505.
34. Ishitsuka K., Tamura K. Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur. J. Haematol. 2008, 80:185-196.
35. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
36. Reed J.C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008, 111:3322-3330.
37. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
38. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
39. Chen S., Dai Y., Harada H., Dent P., Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007, 67:782-791.
40. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
41. Chen R., Keating M.J., Gandhi V., Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005, 106:2513-2519.
42. Gojo I., Zhang B., Fenton R.G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. 2002, 8:3527-3538.
43. Vogler M., Butterworth M., Majid A., Walewska R.J., Sun X.M., Dyer M.J., Cohen G.M. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009, 113:4403-4413.
44. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
45. Slee E.A., Harte M.T., Kluck R.M., Wolf B.B., Casiano C.A., Newmeyer D.D., Wang H.G., Reed J.C., Nicholson D.W., Alnemri E.S., Green D.R., Martin S.J. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 1999, 144:281-292.
46. Chauhan D., Velankar M., Brahmandam M., Hideshima T., Podar K., Richardson P., Schlossman R., Ghobrial I., Raje N., Munshi N., Anderson K.C. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007, 26:2374-2380.